Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study

To the Editor:

Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting people aged 50 years or older. PMR usually improves with glucocorticoids (GC), with rapid resolution of symptoms in response to 15–20 mg/day prednisone1. However, around half of the patients with PMR experience a flare of disease when GC are tapered or stopped, and these patients may require longer GC treatment because of repeated relapses, leading to undesirable side effects. In addition, some patients with PMR have a partial response or do not respond to initial GC treatment1. In this setting, alternative treatments, namely GC-sparing agents, are required. Methotrexate gave conflicting results in PMR while tumor necrosis factor-α inhibitors failed to prevent relapses in randomized controlled studies.

Data suggest that interleukin 6 (IL-6) contributes to the inflammatory process of PMR2: Increased serum levels of IL-6 have been described in PMR and correlate with disease activity3; the risk of recurrence/relapse of PMR is associated with persistent elevated IL-6 serum levels as well as with a genetic polymorphism of the IL-6 promoter gene3; and reports described the efficacy of tocilizumab (TCZ), an anti-IL-6 receptor agent, in the treatment of giant cell arteritis (GCA)4,5. The clinical value of TCZ in isolated PMR is less well described. This prompted us to analyze the potential use of this biological agent in patients with isolated PMR who are refractory or intolerant to GC.

A call to observe all cases of patients with PMR who received at least 1 infusion of TCZ was sent to the members of the French specialist network Club Rhumatismes et Inflammation (including rheumatologists and specialists in internal medicine). Patients had to satisfy the Healey criteria for PMR6 and have pure or predominant PMR clinical features.

During a 24-month period (2013–2014), 7 cases were declared (Table 1). Included patients (4 men) had a mean age of 73.4 ± SD 7.9 and a mean duration of disease at time of TCZ initiation of 2.3 ± 1.6 years. They all had negative rheumatoid factor and anticyclic citrullinated peptide antibodies. The mean duration of GC treatment was 16.1 ± 9.2 months (range 1–48). Clinical features were pure PMR for 6 patients while 1 patient had PMR with biopsy-proven GCA, but without any related symptoms. Five patients had GC-refractory disease requiring a daily prednisone dosage of 20.7 ± 4.5 mg. Two patients had concomitant metabolic diseases (diabetes and metabolic syndrome), and TCZ was thus started shortly after GC initiation (1 and 2 months, respectively). Similarly, for 2 other patients, TCZ was introduced shortly after PMR diagnosis to avoid GC side effects. Immunosuppressive agents were given prior to TCZ in all patients, without significant improvement.

The patients received TCZ 8 mg/kg monotherapy monthly with a dramatic clinical improvement in all within 4 to 8 weeks. There was a simultaneous decrease in the PMR activity score and C-reactive protein levels (Figure 1). Four patients achieved low disease activity, 2 medium disease activity, and 1 patient still had high disease activity despite improvement. This was explained by persistent high visual analog scale and morning stiffness according to the patient. In parallel, GC dosage was tapered to 2.5 ± 2.2 mg. The mean number of TCZ infusions was 10.4 ± 6.6 (range 2–22). Patients were followed up for 19.4 ± 7.1 months; 4 stopped TCZ without relapse and 3 required treatment maintenance with TCZ. Finally, treatment was well tolerated without adverse events.

Seven similar cases of pure PMR treated by TCZ have previously been reported7,8,9,10, while a substantially higher number of patients with GCA have received this biological agent4,5. In PMR cases, TCZ was given as a monthly 8 mg/kg infusion with a clinical response observed within 4 to 12 weeks. These patients had GC-resistant PMR with active disease despite immunosuppressive drugs, or they had safety concerns with GC. The clinical response was good except in 1 patient who failed to respond7. The followup period was generally 6 months without data on longterm outcome. Our series is in line with these results with a short time of response. In addition, the longterm followup indicates sustained response to TCZ in most of our patients. Mounting evidence suggests that IL-6 plays a major role in sustaining disease activity in PMR and its related disorder, GCA. Tocilizumab led to favorable results in GCA-specific symptoms and also in associated PMR4,5.

Taken together, these results strongly support the hypothesis that TCZ monotherapy is an active biological drug in the treatment of PMR and/or GCA as an adjunctive therapy for patients who have GC-refractory disease, and for those with GC side effects. Since GC remain a mainstay of therapy for these conditions, the appropriate time and context in which to introduce TCZ remain to be determined. In our series, TCZ was effective in patients who remained refractory after several months of GC, but also in the early phase of PMR. Remission was achieved in 3 cases after a limited number of TCZ infusions given shortly after GC initiation, and these patients had no relapse, suggesting that TCZ may be very effective when given early. Alternatively, when TCZ was given after a long duration of GC therapy, a clinical response was also obtained, but maintenance of the biological agent

Table 1. Clinical features, therapy, and outcomes of 7 patients with isolated PMR treated with TCZ. CRP levels and GC dosage were given before initiating TCZ and after the last TCZ infusion.

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Yrs/Sex</th>
<th>Duration of GC Therapy before Initiating TCZ, Mos</th>
<th>Previous Drugs before TCZ</th>
<th>PMR-AS at the Start of TCZ</th>
<th>PMR-AS after TCZ, Last Assessment</th>
<th>CRP at the Start of TCZ, mg/l</th>
<th>CRP after TCZ, mg/l, Last Assessment</th>
<th>GC Dosage at the Start of TCZ, mg</th>
<th>GC Dosage after TCZ, Infusions, mg/l</th>
<th>No. TCZ Infusions</th>
<th>Followup Duration, Mos</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>65/M</td>
<td>20</td>
<td>MTX</td>
<td>41</td>
<td>23</td>
<td>30</td>
<td>5</td>
<td>15</td>
<td>0</td>
<td>19</td>
<td>20 TCZ ongoing</td>
</tr>
<tr>
<td>2</td>
<td>78/F</td>
<td>36</td>
<td>IFX, ADA</td>
<td>25</td>
<td>12</td>
<td>25</td>
<td>1</td>
<td>20</td>
<td>6</td>
<td>22</td>
<td>22 TCZ ongoing</td>
</tr>
<tr>
<td>3</td>
<td>80/M</td>
<td>1</td>
<td>MTX</td>
<td>37</td>
<td>1.5</td>
<td>100</td>
<td>5</td>
<td>25</td>
<td>0</td>
<td>2</td>
<td>20 TCZ stopped</td>
</tr>
<tr>
<td>4</td>
<td>74/M</td>
<td>4</td>
<td>MTX</td>
<td>40</td>
<td>1.5</td>
<td>119</td>
<td>5</td>
<td>25</td>
<td>0</td>
<td>3</td>
<td>20 TCZ stopped</td>
</tr>
<tr>
<td>5</td>
<td>71/F</td>
<td>2</td>
<td>MTX, LFM</td>
<td>26</td>
<td>7</td>
<td>50</td>
<td>7</td>
<td>20</td>
<td>2.5</td>
<td>21</td>
<td>25 TCZ stopped</td>
</tr>
<tr>
<td>6</td>
<td>84/F</td>
<td>3</td>
<td>MTX</td>
<td>26</td>
<td>2</td>
<td>40</td>
<td>5</td>
<td>25</td>
<td>5</td>
<td>2</td>
<td>25 TCZ stopped</td>
</tr>
<tr>
<td>7</td>
<td>62/M</td>
<td>48</td>
<td>MTX, ETA, ADA</td>
<td>24</td>
<td>2</td>
<td>2.9</td>
<td>2</td>
<td>15</td>
<td>4</td>
<td>4</td>
<td>4 TCZ ongoing</td>
</tr>
</tbody>
</table>

Mean ± SD 73.4 ± 7.9 16.1 ± 9.2 32.3 ± 7.8 7.0 ± 4.1 56.9 ± 24.1 4.2 ± 2.1 20.7 ± 4.5 2.5 ± 2.2 10.4 ± 6.6 19.4 ± 7.1

PMR: polymyalgia rheumatica; TCZ: tocilizumab; CRP: C-reactive protein; GC: glucocorticoids; PMR-AS: PMR activity score; M: male; F female; MTX: methotrexate; IFX: infliximab; ADA: adalimumab; LFM: leflunomide; ETA: etanercept.
was necessary. Thus, future studies must clarify the indications, when to introduce it, the predictive factors for good response, and the duration of TCZ therapy in the management of PMR.

ÉRIC TOUSSIROT, MD, PhD, Professor, Clinical Investigation Center in Biotherapy, Institut national de la santé et de la recherche médicale, Centre Investigation Clinique-1431, Fédération Hospitalo-Universitaire INCREASE, University Hospital of Besançon, and Department of Rheumatology, University Hospital of Besançon, and Department of Therapeutics and EA 4266 “Pathogens and Inflammation”, Structure Fédérative de Recherche 4234, University of Franche-Comté, Besançon, France; ANTOINE MARTIN, MD, Department of Rheumatology, Hospital of Saint-Brieuc, Saint-Brieuc, France; MARTIN SOUBRIER, MD, PhD, Professor, Department of Rheumatology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France; SERGE REDEKER, MD, Department of Internal Medicine, Hospital of Abbeville, Abbeville, France; ALEXIS RÉGENT, MD, Department of Internal Medicine, University Hospital of Cochin, Paris, France. Address correspondence to Dr. Eric Toussirot, University Hospital, Clinical Investigation Center-Biotherapy, CHU Hospital St Jacques, Bat St Joseph, Besançon, 25000, France. E-mail: etoussirot@chu-besancon.fr

ACKNOWLEDGMENT

The authors are indebted to the Club Rhumatismes et Inflammation (Le CRI) for its help in conducting the study.

REFERENCES